Research work · 2015
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Marc Steven Sabatine, Robert Patrick Giugliano, Stephen D. Wiviott
New England Journal of Medicine
Abstract
To convert the values for low-density lipoprotein (LDL) cholesterol to millimoles per liter, multiply by 0.02586.† Included in this category is the number of patients who underwent randomization and received at least one dose of a study drug.‡ Patients who were enrolled in phase 2 parent trials and who agreed to participate in the extension study were enrolled in OSLER-1.§ Patients who were enrolled in phase 3 parent trials and who agreed to participate in the extension study were enrolled in OSLER-2.